Composition for Long-Acting Peptide Analogs

• US 20110207662A1
• Filed: 04/27/2011
• Published: 08/25/2011
• Est. Priority Date: 08/03/2007
• Status: Active Grant

• Current Assignee: Pharmain Corporation
• Original Assignee: Pharmain Corporation
• Inventors: Bolotin, Elijah M., Castillo, Gerardo M.
• Granted Patent: US 8,518,876 B2
• Time in Patent Office: Days
• US Class Current: 514/5.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/542 Carboxylic acids, e.g. a fatty acid or an amino acid
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 14/485 Epidermal growth factor [EGF], i.e. urogastrone
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides
• CPC Class Codes: C07K 7/16 Oxytocins; Vasopressins; Related peptides

Abstract

The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)_x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (Z_yHis_w)_p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.

Claims

1. A composition comprising a peptide analog having a general formula:

A-(Cm)_x-peptide, wherein;

a. Cm is any one of glycine, alanine, lysine, and arginine;

b. x is an integer from 0-6;

c. A is an alkyl group with 6 to 36 carbon units with a linker group selected from carbonyl, amino, and —

OCH(CH₃)CO—

; and

d. the A-(Cm)_x-peptide has lower biological activity in cell culture than the parent peptide in the absence of serum.

2. The composition of claim 1, further comprising a polymeric carrier with a plurality of hydrophobic groups of 8-36 carbons each, wherein group A of the peptide analog is non-covalently bound to the plurality of hydrophobic groups of the polymeric carrier by hydrophobic interaction.

3. The composition of claim 2, wherein the linker group is —

OCH(CH₃)CO—

.

4. The composition in claim 2, wherein the peptide is selected from vasopressin, glucagon like peptide (GLP), leptin fragment, gastric inhibitory polypeptide (GIP), epidernal growth factor (EGF) receptor ligand, EGF, transforming growth factor alpha (TGF-alpha), gastrin/cholecystokinin receptor ligand, gastrin, cholecystokinin, auristatin, nisin, insulin, insulin-like growth factor, parathyroid hormone (PTH), atrial natriuretic factor, somatostatin, gonadotropin releasing hormone, leutinizing-hormone-releasing-hormone, and vasoactive intestinal peptide (VIP).

5. The composition of claim 2, wherein the peptide is GLP-1 and A-(Cm)_x- is attached to the C terminus of the peptide or a side chain.

6. The composition of claim 2, wherein A is a linear alkyl.

7. The composition of claim 3, wherein A is a linear alkyl.

8. The composition of claim 4, wherein A is a linear alkyl.

9. The composition of claim 5, wherein A is a linear alkyl.

10. The composition of claim 2, wherein A is a branched alkyl.

11. The composition of claim 3, wherein A is a branched alkyl.

12. The composition of claim 4, wherein A is a branched alkyl.

13. The composition of claim 5, wherein A is a branched alkyl.

23. A method of making a peptide analog comprising:

forming a covalent bond between a parent peptide and a group A-(Cm)_x- (reactive group) to form a peptide analog according to claim 1, where said peptide analog has lower biological activity in cell culture than the parent peptide in the absence of serum.

14. A peptide analog having a general formula:

A-(Cm)_x-peptide, wherein;

a. Cm is any one of glycine, alanine, lysine, and arginine;

b. x is an integer from 0-6;

c. A is a chemical group or moiety comprising alkyl group with 6 to 36 carbon units with a —

OCH(CH₃)CO-linker attached to —

(Cm)_x-peptide; and

d. the A-(Cm)_x-peptide has lower biological activity in cell culture than the parent peptide in the absence of serum,

wherein the peptide is not SEQ ID NO;

53.

15. The peptide analog of claim 14, wherein the peptide is selected from glucagon like peptide (GLP), leptin fragment, gastric inhibitory polypeptide (GIP), epidernal growth factor (EGF) receptor ligand, EGF, transforming growth factor alpha (TGF-alpha), gastrin/cholecystokinin receptor ligand, gastrin, cholecystokinin, auristatin, nisin, insulin, insulin-like growth factor, parathyroid hormone (PTH), atrial natriuretic factor, somatostatin, gonadotropin releasing hormone, leutinizing-hormone-releasing-hormone, and vasoactive intestinal peptide (VIP).

16. The peptide analog of claim 14, wherein the peptide is GLP-1 and A-(Cm)_x- is not attached to the N terminus of the peptide.

17. The peptide analog of claim 14, wherein A is a linear alkyl.

18. The peptide analog of claim 15, wherein A is a linear alkyl.

19. The peptide analog of claim 16, wherein A is a linear alkyl.

20. The peptide analog of claim 14, wherein A is a branched alkyl.

21. The peptide analog of claim 15, wherein A is a branched alkyl.

22. The peptide analog of claim 16, wherein A is a branched alkyl.

24. A method for treatment of diabetes in a subject comprising administering the composition of claim 5 or the peptide analog of claim 16 to a patient in need thereof.